- Home
- AMIX vs SONN Comparison
AMIX vs SONN Comparison
Compare AMIX & SONN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMIX
- SONN
- Stock Information
- Founded
- AMIX 2014
- SONN N/A
- Country
- AMIX United States
- SONN United States
- Employees
- AMIX N/A
- SONN N/A
- Industry
- AMIX
- SONN Biotechnology: Pharmaceutical Preparations
- Sector
- AMIX
- SONN Health Care
- Exchange
- AMIX NYSE
- SONN Nasdaq
- Market Cap
- AMIX 3.5M
- SONN 3.8M
- IPO Year
- AMIX N/A
- SONN N/A
- Fundamental
- Price
- AMIX $1.58
- SONN $6.12
- Analyst Decision
- AMIX Strong Buy
- SONN Strong Buy
- Analyst Count
- AMIX 1
- SONN 1
- Target Price
- AMIX $5.00
- SONN $20.00
- AVG Volume (30 Days)
- AMIX 2.4M
- SONN 11.3M
- Earning Date
- AMIX 08-12-2025
- SONN 08-13-2025
- Dividend Yield
- AMIX N/A
- SONN N/A
- EPS Growth
- AMIX N/A
- SONN N/A
- EPS
- AMIX N/A
- SONN N/A
- Revenue
- AMIX N/A
- SONN $1,000,000.00
- Revenue This Year
- AMIX N/A
- SONN $5,376.22
- Revenue Next Year
- AMIX N/A
- SONN N/A
- P/E Ratio
- AMIX N/A
- SONN N/A
- Revenue Growth
- AMIX N/A
- SONN 978.39
- 52 Week Low
- AMIX $1.14
- SONN $1.08
- 52 Week High
- AMIX $42.40
- SONN $19.30
- Technical
- Relative Strength Index (RSI)
- AMIX 56.55
- SONN 65.60
- Support Level
- AMIX $1.35
- SONN $7.63
- Resistance Level
- AMIX $1.70
- SONN $19.30
- Average True Range (ATR)
- AMIX 0.13
- SONN 2.03
- MACD
- AMIX 0.03
- SONN 0.41
- Stochastic Oscillator
- AMIX 86.87
- SONN 32.15
About AMIX AUTONOMIX MEDICAL INC
Autonomix Medical Inc is a development-stage medical device development company focused on advancing technologies for sensing and treating disorders relating to the nervous system. Its first-in-class technology platform includes a catheter-based microchip-enabled array that can detect and differentiate neural signals with a high degree of sensitivity as demonstrated in animal studies.
About SONN Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.